Publication - Progress report
New Medicines Reviews 2013
Reports on the role of SMC & Review of IPTR & ADTC
Appendix 6: CMO(2012)1 guidance example list of SMC medicines and formulary decisions
| SMC accepted medicine | Indication | Formulary decision & rationale for non-inclusion | Date |
|---|---|---|---|
| e.g. Everolimus (Afinitor) | Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease. | Not included - pending protocol | 04/02/2013 |
Contact
Email: VERONICA MOFFAT